TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30865315
Drug: 75-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg single-dose solriamfetol in severe renal impairment
Study: 30865315
Drug: 75-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg single-dose solriamfetol in ESRD without hemodialysis
Study: 30865315
Drug: 75-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg single-dose solriamfetol in ESRD with hemodialysis
Study: 30865315
Drug: 75-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg single-dose solriamfetol in ESRD with and without hemodialysis
Study: 30865315
Drug: 75-mg single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg single-dose solriamfetol during hemodialysis
Study: 30865315
Drug: Study drug-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug-related adverse events
Study: 30583748
Drug: Circulating bio‐ADM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating bio‐ADM levels upon admission > 70 pg/ml
Study: 26992115
Drug: Bioabsorbable steroid-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable steroid-eluting sinus implant (mometasone furoate)
Study: 25262257
Drug: Single-antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-antiplatelet therapy (SAPT)
Study: 17436202
Drug: Echinacea supplement
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea supplement for 4 weeks
Study: 16214443
Drug: Pravastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin treatment for 6 months
Study: 12001761
Drug: Valproate or
Normalized name: valproate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate or carbamazepine in monotherapy or combination of phenobarbital and phenytoin and the combination of phenobarbital, phenytoin and primidone in polytherapy
Study: 10544903
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) given as an intravenous bolus of 80 U/kg followed by a constant infusion of 18 U/kg/h
Study: 10544903
Drug: Nadroparin 185
Normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 185 AXa IU/kg once daily subcutaneously
Study: 7792126
Drug: Amoxicillin-clavulanate (amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (amoxicillin 40 mg/kg/day 3 times a day)
Study: 1977256
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for 30, 60, 90, and 120 min on various body locations.
Study: 1977256
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream on the back.
Study: 1977256
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream in the cubital fossa and on the hand.
Study: 25533243
Drug: 5Hz‐rTMS (treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5Hz‐rTMS (treatment)
Study: 19494551
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tests for orientation, memory, attention, executive function, and abstraction and judgment
Study: 19494551
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tests for memory, attention, executive function, and abstraction and judgment (excluding orientation)
Study: 16423089
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg q.d., esomeprazole 20 mg b.i.d., and amoxicillin 1 g b.i.d.
Study: 16423089
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.
Study: 15598479
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg tablet
Study: 15598479
Drug: Gefitinib dispersion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib dispersion preparation via drink
Study: 15598479
Drug: Gefitinib dispersion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib dispersion preparation via nasogastric tube
Study: 11306524
Drug: CEE+MP (micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE+MP (micronized progesterone 200 mg)
Study: 11306524
Drug: CEE+MPA (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE+MPA (medroxyprogesterone acetate 10 mg)
Study: 9403262
Drug: Stoxil topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stoxil topical ointment
Study: 29032139
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg twice daily (50 mg once daily if treated with a sulfonylurea)
Study: 20156151
Drug: Intraperitoneal drug
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal drug therapy (IP chemotherapy)
Study: 20156151
Drug: Intraperitoneal drug
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal drug therapy
Study: 9364183
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone 1000 micrograms twice daily for three months
Study: 9364183
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 30 mg/day for ten days after each treatment phase
Study: 2419692
Drug: Pinacidil 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 37.5 mg
Study: 2419692
Drug: Pinacidil 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 37.5 mg + Propranolol 40 mg
Study: 20394495
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azelaic acid 5% and erythromycin 2% gel (AzE)
Study: 18661887
Drug: High-protein, high-caloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein, high-caloric supplement (3 daily servings)
Study: 11803323
Drug: Dopamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (2 mg/kg x min)
Study: 22211362
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of cloprostenol (87.5 μg; 1.0 ml; i.m.)
Study: 22211362
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of cloprostenol (43.75 μg; 0.5 ml)
Study: 22211362
Drug: One third
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One third dose of cloprostenol (26.25 μg; 0.3 ml)
Study: 19205289
Drug: Inhaled budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide, 800 microg/d during pollen season
Study: 11605103
Drug: High soya
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High soya diet (100 mg total isoflavones/day)
Study: 11605103
Drug: Low soya
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low soya diet (0.5 mg total isoflavones/day)
Study: 9623031
Drug: Risperidone, final
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone, final dose 6 mg
Study: 8076566
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine gel applied to the throat for 20 minutes
Study: 8076566
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine solution administered by gargling for five minutes
Study: 1091183
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of haloperidol
Study: 31843007
Drug: Delayed RRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed RRT strategy (RRT initiated only if a potentially severe condition occurs or serum urea concentration reaches 50 mmol/l)
Study: 26611718
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day omega-3 fatty acid from flaxseed oil
Study: 23948819
Drug: NWB bi-weekly
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NWB bi-weekly group exercise class
Study: 19336785
Drug: Routine psychosocial
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine psychosocial care and selective serotonin reuptake inhibitors (SSRIs)
Study: 19336785
Drug: Routine psychosocial
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine psychosocial care, selective serotonin reuptake inhibitors (SSRIs), and cognitive-behavioural therapy (CBT)
Study: 11775133
Drug: COER-verapamil (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: COER-verapamil (180 to 540 mg/day)
Study: 7986516
Drug: Subcutaneous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous verapamil
Study: 25652104
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg nebulized magnesium
Study: 19080649
Drug: Firebird DES
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firebird DES implantation and Tirofiban intravenous injection (10 microg x kg(‐1) within 3 minutes followed by 0.15 microg x kg(‐1) x min(‐1) for 36 hours)
Study: 2208024
Drug: Intraarterial cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial cisplatin (DDP) with systemic doxorubicin, high-dose methotrexate, and ifosfamide
Study: 2208024
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin (DDP) with systemic doxorubicin, high-dose methotrexate, and ifosfamide
Study: 38180
Drug: Treatment (specifics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (specifics not provided)
Study: 31202506
Drug: 50-mg udenafil
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg udenafil BID
Study: 25936684
Drug: High-dose (71ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (71ml) GRE acquisitions
Study: 25936684
Drug: Low-dose (24ml)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (24ml) GRE scans
Study: 25936684
Drug: High-dose (71ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (71ml) 3D-radial acquisitions
Study: 25936684
Drug: Low-dose (24ml)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (24ml) 3D-radial acquisitions
Study: 24169052
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (BUD), 800 micrograms
Study: 15822550
Drug: Aspiration combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration combined with methylprednisolone acetate injection plus wrist immobilization
Study: 8598434
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diet and exercise
Study: 8160980
Drug: Mannitol 0.5
Normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 0.5 g/kg in Group M
Study: 20409444
Drug: Antidepressant discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant discontinuation
Study: 27162089
Drug: Cabotegravir 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotegravir 150 mg (30 mg × 5 tablets) every 12 hours for a total of 3 doses over 2 days
Study: 27162089
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (single open-label dose)
Study: 15136379
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg bid)
Study: 9494320
Drug: 1,800 cGy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,800 cGy whole brain radiation therapy (WBRT) plus intrathecal methotrexate (IT MTX)
Study: 3326926
Drug: LHRH nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH nasal spray (400 micrograms three times a day for 28 days)
Study: 31870562
Drug: Daily supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplement drink enriched with omega-3 fatty acids and vitamin D plus additional olive oil and olive oil-based spread
Study: 29276990
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) plus care as usual
Study: 22858745
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg INK
Study: 22858745
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg INK
Study: 22858745
Drug: 9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/kg INK
Study: 18502003
Drug: DNA‐C priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA‐C priming (4 mg/ml) given intramuscularly at weeks 0 and 4 plus NYVAC‐C at weeks 20 and 24
Study: 15316827
Drug: PSteE-milk (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSteE-milk (2.0 g plant sterols/d)
Study: 15316827
Drug: PSteE-spread (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSteE-spread (4 g plant sterols/d)
Study: 15316827
Drug: PSteE-yoghurt (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSteE-yoghurt (1.8 g plant sterols/d)
Study: 15316827
Drug: PStaE-yoghurt (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: PStaE-yoghurt (1.7 g plant stanols/d)
Study: 15316827
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PSteE-milk and PSteE-spread
Study: 10497456
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl (25 micrograms with 12 mg of hyperbaric bupivacaine 0.75%)
Study: 10497456
Drug: Preservative-free normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free normal saline (0.5 mL with 12 mg of hyperbaric bupivacaine 0.75%)
Study: 24388737
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.1 μg/kg/min and demand boluses of 0.1 μg/kg
Study: 19177029
Drug: Pharmacogenetics-guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetics-guided dosing for warfarin therapy
Study: 19177029
Drug: Traditional dosing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dosing for warfarin therapy
Study: 17640542
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment with combination of antiplatelet and anticoagulant therapy, early coronary angiography, revascularization, and anti-ischemic medical therapy.
Study: 15274397
Drug: Methotrexate-modulated continuous
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate-modulated continuous infusion of 5-fluorouracil (ci5-FU/MTX)
Study: 11762659
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (500 units, five tablets per day)
Study: 11762659
Drug: Placebo (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (five placebo tablets per day)
Study: 8220143
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mitozantrone and ifosfamide
Study: 8220143
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent mitozantrone
Study: 3602025
Drug: Alizapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (5 mg/kg/day, oral route)
Study: 3602025
Drug: Alizapride (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (intravenous and oral routes)
Study: 23401447
Drug: Elesclomol 213
Normalized name: Élesclomol
DrugBank: Elesclomol (DB05719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elesclomol 213 mg/m2 plus paclitaxel 80 mg/m2
Study: 23401447
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 alone
Study: 8087352
Drug: Nasal and
Normalized name: Nasal and Sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal and oral endotracheal intubation with gastric intubation performed via the same route in Group 1 patients
Study: 2767860
Drug: B subunit‐killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit‐killed whole cell (BS‐WC) oral cholera vaccine
Study: 2767860
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole cell‐only (WC) oral cholera vaccine
Study: 1221432
Drug: delta9-THC (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: delta9-THC (25 mg)
Study: 1221432
Drug: CBN (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBN (50 mg)
Study: 1221432
Drug: delta9-THC (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: delta9-THC (25 mg) + CBN (50 mg)
Study: 23429495
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg subcutaneously twice weekly with gemcitabine
Study: 15534159
Drug: Nortriptyline combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline combined with transdermal nicotine (nortriptyline started at 25 mg, titrated to 75 mg/d for 12 weeks; transdermal nicotine at 21 mg/d for 8 weeks)
Study: 11575536
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (50 mg/kg bolus followed by 15 mg x kg(‐1) x h(‐1) for 6 h)
Study: 7810638
Drug: Acipimox (antilipolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (antilipolytic agent)
Study: 786686
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (45 mg Zn++) with tetracycline hydrochloride (500 mg)
Study: 786686
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (45 mg Zn++) with doxycycline chloride (200 mg)
Study: 31004853
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including intravenous, topical, and combined)
Study: 23200272
Drug: TMZ 140
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 140 mg/d
Study: 23200272
Drug: TMZ 70
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 70 mg/d
Study: 23200272
Drug: TMZ 140
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 140 mg/d and TMZ 70 mg/d
Study: 14512806
Drug: Rye bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye bran bread (295 g daily)
Study: 14512806
Drug: Wheat bread
Normalized name: Nutritional Supplement Oral Food, Solid [DIETARY SPECIALTIES WHEAT BREAD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bread (275 g daily, control)
Study: 1651893
Drug: Rebamipide 300
Normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide 300 mg/day orally for 7 days
Study: 1651893
Drug: Rebamipide 10
Normalized name: Rebamipide 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide 10 mg/kg, i.v.
Study: 1651893
Drug: Rebamipide 10
Normalized name: Rebamipide 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide 10 mg/kg/hr, i.v.
Study: 1651893
Drug: Rebamipide (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (10, 30, 100, 300 mg/kg, i.p.)
Study: 26087303
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) plus usual care (UC)
Study: 21527577
Drug: High red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: High red meat diet (420 g/d)
Study: 21527577
Drug: Low red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low red meat diet (60 g/d)
Study: 11101476
Drug: Vegetarian diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetarian diet (0 g/d)
Study: 21527577
Drug: Medium red
Normalized name: Loreal 5RB Medium Reddish Brown Hair Color
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium red meat diet (120 g/d)
Study: 14652358
Drug: Sodium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium supplementation (NaSp) treatment (120 mmol Na+/d)
Study: 1512151
Drug: Hyperthermia twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia twice a week (57.8% complete response rate)
Study: 1512151
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (56.3% complete response rate)
Study: 17330831
Drug: Metformin (1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1700 mg/day)
Study: 22119204
Drug: ADT+DE (androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT+DE (androgen deprivation therapy + docetaxel-estramustine)
Study: 22119204
Drug: Chemotherapy (docetaxel-estramustine)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (docetaxel-estramustine)
Study: 15755856
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplementation (1000 mg Ca/d)
Study: 12149511
Drug: Saliva IgM
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saliva IgM and IgA antibodies to E. coli O157 lipopolysaccharide (LPS)